Imaging Biometrics’ oral gallium maltolate treatment shows safety
Imaging Biometrics Ltd has published positive Phase 1 results for its oral gallium maltolate treatment in recurrent glioblastoma. The drug was found safe and well tolerated at all dose levels.
One patient has been on treatment for over 38 months, and the company is reactivating its Expanded Access Programme for up to 20 additional patients.
Rome Resources Plc is launching its first field programme at its New Brunswick tin-tungsten-indium project in Canada, with plans to spend up to CA$150,000.
London BTC Company Ltd has staked its first US gold project, securing 111 mineral claims in Nevada’s Humboldt County, while Zephyr Energy PLC has cleared a key hurdle at its Paradox project in Utah.